A Phase I, Open-Label Dose Escalation and Dose Expansion Study ofIntravenous GFH009 Single Agent in Patients with Relapsed/ Refractory Hematologic Malignancies
MD Anderson Study Status
GFH009 is a potent and highly selective CDK9 inhibitor. The study consists of a dose escalation and a dose expansion part. The purpose of this study is to investigate the safety and tolerability of GFH009 in relapsed/refractory hematologic malignancies [acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphoma], will also explore the preliminary anti-tumor activities of GFH009 in the studied population.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
For general questions about clinical trials: